interferon beta 1bhttp://www.unboundmedicine.com/medline/ebm/research/interferon_beta_1bUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.Do interferon beta-1b and glatiramer acetate grow brain?http://www.unboundmedicine.com/medline/ebm/record/19909906/full_citation/Do_interferon_beta_1b_and_glatiramer_acetate_grow_brainRudick RA, Fisher E 
Do interferon beta-1b and glatiramer acetate grow brain? [Comment, Letter]
Lancet Neurol 2009 Dec; 8(12):1085-6; author reply 1086-7.
Full Citation | Find Related Articles Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.http://www.unboundmedicine.com/medline/ebm/record/19901165/full_citation/Magnetic_resonance_imaging_predictors_of_conversion_to_multiple_sclerosis_in_the_BENEFIT_study_Moraal B, Pohl C, Uitdehaag BM, et al. 
Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. [Journal Article, Research Support, Non-U.S. Gov't]
Arch Neurol 2009 Nov; 66(11):1345-52.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Cutaneous Vasculitis Associated With Interferon beta-1b Treatment for Multiple Sclerosis.http://www.unboundmedicine.com/medline/ebm/record/19820436/full_citation/Cutaneous_Vasculitis_Associated_With_Interferon_beta_1b_Treatment_for_Multiple_Sclerosis_Szilasiová J, Gdovinová Z, Jautová J, et al. 
Cutaneous Vasculitis Associated With Interferon beta-1b Treatment for Multiple Sclerosis. [JOURNAL ARTICLE]
Clin Neuropharmacol 2009 September/October; 32(5):301-303.
Abstract | Full CitationSerum levels of CXCL13 are elevated in active multiple sclerosis.http://www.unboundmedicine.com/medline/ebm/record/19805441/full_citation/Serum_levels_of_CXCL13_are_elevated_in_active_multiple_sclerosis_Festa ED, Hankiewicz K, Kim S, et al. 
Serum levels of CXCL13 are elevated in active multiple sclerosis. [JOURNAL ARTICLE]
Mult Scler 2009 Oct 5.
Abstract | Full Citation | Publisher Full Text | Find Related Articles A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.http://www.unboundmedicine.com/medline/ebm/record/19797261/full_citation/A_single_centre_randomized_double_blind_placebo_controlled_study_of_interferon_beta_1b_on_primary_progressive_and_transitional_multiple_sclerosis_Montalban X, Sastre-Garriga J, Tintoré M, et al. 
A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. [JOURNAL ARTICLE]
Mult Scler 2009 Sep 29.
Abstract | Full Citation | Publisher Full Text | Find Related Articles A reassessment of the plateauing relationship between T2 lesion load and disability in MS.http://www.unboundmedicine.com/medline/ebm/record/19794123/full_citation/A_reassessment_of_the_plateauing_relationship_between_T2_lesion_load_and_disability_in_MS_Sormani MP, Rovaris M, Comi G, et al. 
A reassessment of the plateauing relationship between T2 lesion load and disability in MS. [JOURNAL ARTICLE]
Neurology 2009 Sep 30.
Abstract | Full Citation | Publisher Full Text | Find Related Articles Uncertain BENEFIT of early interferon beta-1b treatment.http://www.unboundmedicine.com/medline/ebm/record/19748320/full_citation/Uncertain_BENEFIT_of_early_interferon_beta_1b_treatment_Pittock SJ 
Uncertain BENEFIT of early interferon beta-1b treatment. [LETTER]
Lancet Neurol 2009 Sep 10.
Full Citation | Publisher Full Text | Find Related Articles Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.http://www.unboundmedicine.com/medline/ebm/record/19748319/full_citation/Long_term_effect_of_early_treatment_with_interferon_beta_1b_after_a_first_clinical_event_suggestive_of_multiple_sclerosis:_5_year_active_treatment_extension_of_the_phase_3_BENEFIT_trial_Kappos L, Freedman MS, Polman CH, et al. 
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. [JOURNAL ARTICLE]
Lancet Neurol 2009 Sep 10.
Abstract | Full Citation | Find Related Articles Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.http://www.unboundmedicine.com/medline/ebm/record/19739877/full_citation/Comparing_the_cost_effectiveness_of_disease_modifying_drugs_for_the_first_line_treatment_of_relapsing_remitting_multiple_sclerosis_Goldberg LD, Edwards NC, Fincher C, et al. 
Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [Journal Article]
J Manag Care Pharm 2009 Sep; 15(7):543-55.
Abstract | Full Citation | Find Related Articles [Therapy of multiple sclerosis]http://www.unboundmedicine.com/medline/ebm/record/19731815/full_citation/[Therapy_of_multiple_sclerosis]Simó M 
[Therapy of multiple sclerosis] [English Abstract, Journal Article]
Neuropsychopharmacol Hung 2009 Mar; 11(1):23-6.
Abstract | Full Citation | Find Related Articles